Strasbourg, France, June 6, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, announces that it has presented preliminary Phase I data for TG4050, its individualized neoantigenic cancer vaccine, during a poster presentation at the annual conference of the American Society of Clinical Oncology (ASCO). TG4050 comes from Transgene’s myvac® platform and benefits from NEC’s Artificial Intelligence (AI) technologies.
These new positive preliminary data include the molecular response (circulating tumor DNA). They were obtained in the first patients treated in two multicenter Phase I trials evaluating TG4050 in ovarian cancer and HPV-negative head and neck cancer. The data was presented in person in Chicago (USA), June 5, 2022.
…/…